Mario Saltarelli, M.D., Ph.D.


Mario Saltarelli

Mario Saltarelli M.D. Ph.D. has more than 20 years of leadership experience in the biopharmaceutical sector, where he has focused on the identification, growth, and advancement of therapeutics development pipelines through the application of advanced translational paradigms. Dr. Saltarelli currently serves as Chief Medical Officer of Entrada Therapeutics in Boston. Previously, he served as Chief Medical Officer of Syntimmune, a mid-stage biopharmaceutical company focused on the development of therapeutics for rare autoimmune diseases, which was acquired by Alexion Pharmaceuticals in November 2018. Prior to Syntimmune, Dr. Saltarelli served as senior vice president and head of early development and neurology at Vertex Pharmaceuticals. At Vertex, he led the company’s early development activities, including translational medicine, clinical pharmacology, clinical biomarkers and neurology.

Prior to joining Vertex, Dr. Saltarelli served as chief medical officer at Annexon Biosciences, Inc. and served as the chief science officer and senior vice president of Mallinckrodt. Dr. Saltarelli previously served as senior vice president of clinical development and medical affairs at Shire. He joined Shire from Abbott Laboratories where he served as the divisional vice president, where he was directly accountable for all aspects of clinical development, medical affairs and development strategy for global neuroscience and anesthesia products. Prior to that, he spent seven years at Pfizer Global Research and Development in Connecticut, ultimately as head of the CNS early clinical development group. He previously served as a non-executive director of MindImmune Therapeutics and as Assistant Professor of Neurology at Emory University School of Medicine.

Dr. Saltarelli earned his bachelor of science degree in psychology from the University of Illinois at Urbana-Champaign, a doctor of medicine degree and a doctor of philosophy degree in neuropharmacology from The Johns Hopkins University School of Medicine. He was an intern in internal medicine at the University of Maryland Medical Center and completed neurology residency at The Johns Hopkins Hospital.